Generic Threat Eclipses AstraZeneca's Earnings

Thursday, 1 Nov 2007 | 3:15 PM ET

AstraZeneca said on Thursday its blockbuster cholesterol medicine Crestor faced a generic challenge from Canada's Cobalt Pharmaceuticals, as third-quarter profit fell 14%. David Brennan, CEO of AstraZeneca, speaks to CNBC's Guy Johnson about the company's earnings and the Crestor story.